A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Imagem de Miniatura
Arquivos
art_ESLAM_A_new_definition_for_metabolic_dysfunctionassociated_fatty_liver_2020.PDF (734.92 KB)
Citações na Scopus
2287
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
ESLAM, Mohammed
NEWSOME, Philip N.
SARIN, Shiv K.
ANSTEE, Quentin M.
TARGHER, Giovanni
ROMERO-GOMEZ, Manuel
ZELBER-SAGI, Shira
WONG, Vincent Wai-Sun
DUFOUR, Jean-Francois
SCHATTENBERG, Joern M.
Citação
JOURNAL OF HEPATOLOGY, v.73, n.1, p.202-209, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The exclusion of other chronic liver diseases including ""excess"" alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, ""positive criteria"" to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.
Palavras-chave
MAFLD, Cirrhosis, Diagnostic criteria, Metabolic, NAFLD, Steatohepatitis, Diabetes, Obesity
URI
https://observatorio.fm.usp.br/handle/OPI/37757
Referências
  1. Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014
  2. Ajmera VH, 2017, HEPATOLOGY, V65, P2090, DOI 10.1002/hep.29055
  3. Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
  4. Ampuero J, 2018, ALIMENT PHARM THER, V48, P1260, DOI 10.1111/apt.15015
  5. Araujo J, 2019, METAB SYNDR RELAT D, V17, P46, DOI 10.1089/met.2018.0105
  6. Arrese M, 2019, EXPERT REV GASTROENT, V13, P849, DOI 10.1080/17474124.2019.1649981
  7. Boyle M, 2018, J HEPATOL, V68, P251, DOI 10.1016/j.jhep.2017.11.006
  8. Bril F, 2017, HEPATOLOGY, V65, P1132, DOI [10.1002/hep.28985, 10.1002/hep.2]
  9. Brook RD, 2018, J AM SOC HYPERTENS, V12, P238, DOI 10.1016/j.jash.2018.01.004
  10. Brunt EM, 2019, HEPATOLOGY, V70, P522, DOI 10.1002/hep.30418
  11. Brunt EM, 2003, MODERN PATHOL, V16, P49, DOI 10.1097/01.MP.0000042420.21088.C7
  12. Byrne CD, 2015, J HEPATOL, V62, pS47, DOI 10.1016/j.jhep.2014.12.012
  13. Caldwell S, 2018, J HEPATOL, V68, P391, DOI 10.1016/j.jhep.2017.12.006
  14. Caleyachetty R, 2017, J AM COLL CARDIOL, V70, P1429, DOI 10.1016/j.jacc.2017.07.763
  15. Caussy C, 2018, HEPATOLOGY, V68, P763, DOI 10.1002/hep.29797
  16. Ceballos N, 2017, J STUD ALCOHOL DRUGS, V78, P488, DOI 10.15288/jsad.2017.78.488
  17. Cespiati A, 2020, CURR PHARM DESIGN, V26, P998, DOI 10.2174/1381612826666200122151251
  18. Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
  19. Chen F, 2020, HEPATOLOGY, DOI 10.1002/hep.30908
  20. Chiang DJ, 2014, CLIN LIVER DIS, V18, P157, DOI 10.1016/j.cld.2013.09.006
  21. Cho YK, 2019, METABOLISM, V97, P50, DOI 10.1016/j.metabol.2019.05.002
  22. Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560
  23. Choi HSJ, 2020, HEPATOLOGY, V71, P539, DOI 10.1002/hep.30857
  24. Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
  25. Cotrim HP, 1999, LIVER, V19, P299, DOI 10.1111/j.1478-3231.1999.tb00053.x
  26. De Luca-Johnson J, 2016, DIGEST DIS SCI, V61, P2710, DOI 10.1007/s10620-016-4213-3
  27. Di Angelantonio E, 2016, LANCET, V388, P776, DOI 10.1016/S0140-6736(16)30175-1
  28. Dufour JF, 2016, HEPATOLOGY, V63, P9, DOI 10.1002/hep.28276
  29. EASL, 2016, DIABETOLOGIA, V59, P1121, DOI 10.1007/s00125-016-3902-y
  30. Eckel N, 2018, LANCET DIABETES ENDO, V6, P714, DOI 10.1016/S2213-8587(18)30137-2
  31. Eddowes PJ, 2019, GASTROENTEROLOGY, V156, P1717, DOI 10.1053/j.gastro.2019.01.042
  32. Eslam M, 2020, GASTROENTEROLOGY, V158, P1999, DOI 10.1053/j.gastro.2019.11.312
  33. Eslam M, 2020, NAT REV GASTRO HEPAT, V17, P40, DOI 10.1038/s41575-019-0212-0
  34. Eslam M, 2019, GASTROENTEROLOGY, V157, P590, DOI 10.1053/j.gastro.2019.05.064
  35. Eslam M, 2018, J HEPATOL, V68, P268, DOI 10.1016/j.jhep.2017.09.003
  36. Fracanzani AL, 2017, CLIN GASTROENTEROL H, V15, P1604, DOI 10.1016/j.cgh.2017.04.045
  37. Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
  38. Hulley S. B., 2007, DESIGNING CLIN RES
  39. Inoue Y, 2018, CURR OBES REP, V7, P276, DOI 10.1007/s13679-018-0317-8
  40. Kleiner DE, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12565
  41. Lassale C, 2018, EUR HEART J, V39, P397, DOI 10.1093/eurheartj/ehx448
  42. McPherson S, 2015, J HEPATOL, V62, P1148, DOI 10.1016/j.jhep.2014.11.034
  43. Munoz-Garach A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060320
  44. Pais R, 2013, J HEPATOL, V59, P550, DOI 10.1016/j.jhep.2013.04.027
  45. Rastogi A, 2017, APMIS, V125, P962, DOI 10.1111/apm.12742
  46. Ratziu V, 2016, 67 ANN M AM ASS STUD
  47. Rotman Y, 2017, HEPATOLOGY, V65, P1088, DOI 10.1002/hep.29094
  48. */* S 13, 2018, DIABETES CARE S1, V41, pS1, DOI 10.2337/DC18-S002
  49. Sanchez-Munoz D, 2004, DIGEST DIS SCI, V49, P1957, DOI 10.1007/s10620-004-9600-5
  50. Sarin SK, 2020, LANCET GASTROENTEROL, V5, P167, DOI 10.1016/S2468-1253(19)30342-5
  51. Shea JL, 2011, OBESITY, V19, P624, DOI 10.1038/oby.2010.174
  52. Siddiqui MS, 2018, HEPATOLOGY, V67, P2001, DOI 10.1002/hep.29607
  53. Singal AK, 2018, AM J GASTROENTEROL, V113, P175, DOI 10.1038/ajg.2017.469
  54. Stefan N, 2017, CELL METAB, V26, P292, DOI 10.1016/j.cmet.2017.07.008
  55. Thuluvath PJ, 2018, J HEPATOL, V68, P519, DOI 10.1016/j.jhep.2017.11.018
  56. Vilar-Gomez E, 2018, GASTROENTEROLOGY, V155, P443, DOI 10.1053/j.gastro.2018.04.034
  57. Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038
  58. Wong VWS, 2018, J GASTROEN HEPATOL, V33, P70, DOI 10.1111/jgh.13857
  59. Younossi Z, 2018, J HEPATOL, V69, P1365, DOI 10.1016/j.jhep.2018.08.013
  60. Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03